UP expands Lalitpur Pharma Park, Medical Device & Formulation Park near Noida Airport

Acting on the suggestions received during the Pharma Conclave 1.0 early this week, the Uttar Pradesh government, in order to utilise land in Lalitpur in addition to Noida for bulk drug manufacturing units of the red and orange categories, is accelerating the development of a future-ready pharma ecosystem through UPSIDA’s Lalitpur Pharma Park.

The conclave highlighted Uttar Pradesh’s emergence as a business-friendly and investment-ready hub for pharmaceutical manufacturing and healthcare innovation—driven by strong governance, improved law and order, and progressive policy support.

Advertisement

According to officials here on Thursday, Phase I spans 352.91 acres, dedicated to formulation units, bulk drugs, and common infrastructure, while Phase II, covering 1,465 acres, is under development, for which an Expression of Interest (EOI) has been floated. Backed by an overall land bank of nearly 8,000 acres, Uttar Pradesh is strategically positioning itself as a leading destination for pharma investments.

Strengthening this ecosystem further, the Yamuna Expressway Industrial Development Authority is developing a 350-acre Medical Device Park in Sector-28, equipped with advanced testing laboratories and an ASCA certification facility to reduce dependence on overseas testing. Additionally, a 250-acre Pharma Formulation Park is planned in Sector 7 near the Noida International Airport, reinforcing Uttar Pradesh’s potential to emerge as North India’s key healthcare manufacturing hub with strong export connectivity.

Officials said a major highlight of Pharma Conclave 1.0 was the announcement of an investment intent of nearly Rs 10,000 crore, along with the exchange of 11 Memorandums of Understanding (MoUs) in pharmaceuticals and medical devices. These proposals are expected to significantly enhance manufacturing capacity, generate employment, and strengthen healthcare supply chains—accelerating the overall growth of the State’s pharma sector.

Pharma Conclave 1.0 strongly underscored the importance of building a resilient research and innovation backbone. Leading scientists and institutional representatives—including Dr Radha Rangarajan (CDRI), Prof Shubhini A. Saraf (NIPER Raebareli), Dr Neelima Mishra (National Institute of Biologicals), and Dr Seema Pai (ISCR)—shared valuable insights on strengthening scientific capabilities in the State.

The conclave saw strong participation from leading pharma companies, highlighting interest in expanding operations in Uttar Pradesh. Stakeholders discussed growth, investments, and partnerships, reaffirming the State as a preferred destination. Infrastructure emerged as key, with leaders stressing plug-and-play facilities, ready land, and compliance-ready spaces to fast-track projects and boost competitiveness.

The conclave also highlighted the critical role of policy support and regulatory facilitation in shaping the State’s pharma growth trajectory.